Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats

Behavioural Brain Research

Volumn 216, Issue 1, 2011, Pages 129-135

  Jungnickel, Julia ^a   Kalve, Ieva ^a,c   Reimers, Linda ^a   Nobre, André ^a,c   Wesemann, Maike ^a   Ratzka, Andreas ^a   Halfer, Nina ^a   Lindemann, Christoph ^a,c   Schwabe, Kerstin ^a,c   Töllner, Kathrin ^b,c   Gernert, Manuela ^b,c   Grothe, Claudia ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

6 OHDA lesioned rats; Anxiety like behavior; Dopaminergic progenitors; Locomotor activity; Transplantation

Indexed keywords

APOMORPHINE; DOPAMINE; OXIDOPAMINE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CELL LOSS; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; FOREBRAIN; LOCOMOTION; MAZE TEST; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REARING; STRIATE CORTEX; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; BRAIN TISSUE TRANSPLANTATION; CORPUS STRIATUM; DOPAMINE; FEMALE; FETAL TISSUE TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; NEURONS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 78149410580     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.07.023     Document Type: Article

References (42)

1. Bjorklund A., Stenevi U., Schmidt R.H., Dunnett S.B., Gage F.H. Intracerebral grafting of neuronal cell suspensions. I. Introduction and general methods of preparation. Acta Physiol Scand Suppl 1983, 522:1-7.
2. Bjorklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007, 30:194-202.
3. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., et al. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 2008, 86:2050-2061.
4. Breysse N., Carlsson T., Winkler C., Bjorklund A., Kirik D. The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. J Neurosci 2007, 27:5849-5856.
5. Burt D.R., Enna S.J., Creese I., Snyder S.H. Dopamine receptor binding in the corpus striatum of mammalian brain. Proc Natl Acad Sci USA 1975, 72:4655-4659.
6. Carlsson T., Carta M., Winkler C., Bjorklund A., Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007, 27:8011-8022.
7. Carlsson T., Carta M., Munoz A., Mattsson B., Winkler C., Kirik D., et al. Impact of grafted serotonin and dopamine neurons on development of l-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
8. Costall B., Marsden C.D., Naylor R.J., Pycock C.J. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain. Brain Res 1976, 118:87-113.
9. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994, 49:171-176.
10. Dunnett S.B., Robbins T.W. The functional role of mesotelencephalic dopamine systems. Biol Rev Camb Philos Soc 1992, 67:491-518.
11. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719.
12. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic. II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987, 7:3915-3934.
13. Hahn M., Timmer M., Nikkhah G. Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease. J Neurosci Res 2009, 87:2006-2019.
14. Hefti F., Melamed E., Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980, 195:123-137.
15. Henderson R., Kurlan R., Kersun J.M., Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992, 4:257-264.
16. Karstaedt P.J., Kerasidis H., Pincus J.H., Meloni R., Graham J., Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol 1994, 126:25-30.
17. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) 2008, 197:279-293.
18. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247:574-577.
19. Lynd-Balta E., Haber S.N. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 1994, 59:625-640.
20. Mayeux R., Stern Y., Williams J.B., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986, 143:756-759.
21. Nikkhah G., Olsson M., Eberhard J., Bentlage C., Cunningham M.G., Bjorklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 1994, 63:57-72.
22. Nikkhah G., Rosenthal C., Falkenstein G., Roedter A., Papazoglou A., Brandis A. Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters. Cell Transplant 2009, 18:119-133.
23. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54:403-414.
24. Parsons L.H., Justice J.B. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 1993, 606:195-199.
25. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
26. Prensa L., Parent A. The nigrostriatal pathway in the rat: a single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J Neurosci 2001, 21:7247-7260.
27. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
28. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
29. Rodriguez-Oroz M.C., Jahanshahi M., Krack P., Litvan I., Macias R., Bezard E., et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009, 8:1128-1139.
30. Schneider F., Althaus A., Backes V., Dodel R. Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci 2008, 258(Suppl. 5):55-59.
31. Starkstein S.E., Merello M., Jorge R., Brockman S., Bruce D., Petracca G., et al. A validation study of depressive syndromes in Parkinson's disease. Mov Disord 2008, 23:538-546.
32. Stein M.B., Heuser I.J., Juncos J.L., Uhde T.W. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990, 147:217-220.
33. Strecker R.E., Sharp T., Brundin P., Zetterstrom T., Ungerstedt U., Bjorklund A. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987, 22:169-178.
34. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
35. Timmer M., Muller-Ostermeyer F., Kloth V., Winkler C., Grothe C., Nikkhah G. Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms. Exp Neurol 2004, 187:118-136.
36. Timmer M., Grosskreutz J., Schlesinger F., Krampfl K., Wesemann M., Just L., et al. Dopaminergic properties and function after grafting of attached neural precursor cultures. Neurobiol Dis 2006, 21:587-606.
37. Torres E.M., Dunnett S.B. Amphetamine induced rotation in the assessment of lesions and grafts in the unilateral rat model of Parkinson's disease. Eur Neuropsychopharmacol 2007, 17:206-214.
38. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
39. Walsh K., Bennett G. Parkinson's disease and anxiety. Postgrad Med J 2001, 77:89-93.
40. Weisskopf M.G., Chen H., Schwarzschild M.A., Kawachi I., Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 2003, 18:646-651.
41. Zetterstrom T., Brundin P., Gage F.H., Sharp T., Isacson O., Dunnett S.B., et al. In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 1986, 362:344-349.
42. Zhou F.C., Bledsoe S., Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 1991, 556:108-116.